Cerity Partners
PACB icon

Cerity Partners’s Pacific Biosciences PACB Stock Holding History

Cerity Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Buy
98,511
+77,090
+360% +$112K ﹤0.01% 3102
2026
Q1 		$28.3K Buy
+21,421
New +$38.3K ﹤0.01% 3157
2025
Q1 		– Sell
-45,110
Closed -$80K – 2583
2024
Q4 		$80K Buy
45,110
+2,193
+5% +$4.28K ﹤0.01% 2354
2024
Q3 		$73K Sell
42,917
-10,126
-19% -$16.6K ﹤0.01% 2455
2024
Q2 		$72.7K Buy
53,043
+21,808
+70% +$44K ﹤0.01% 2144
2024
Q1 		$117K Buy
+31,235
New +$183K ﹤0.01% 2189

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cerity Partners's PACB Position: Q2 2026 in Review

Cerity Partners increased its Pacific Biosciences (PACB) stake by 360% in Q2 2026, buying an estimated $112K and bringing the position to 98,511 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #3102.

Cerity Partners first reported a position in PACB in Q1 2024 and has held it in 6 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Cerity Partners held 98,511 shares of Pacific Biosciences worth $165K as of Q2 2026.
  • Cerity Partners bought 77,090 Pacific Biosciences shares in Q2 2026, an estimated $112K.
  • Pacific Biosciences made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3102 holding.
  • Cerity Partners first reported a position in Pacific Biosciences in Q1 2024 and has held it in 6 quarters since.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.